Get the Stockscreener App
0.5591
8.42%
-0.0514
After Hours:
.57
0.0109
+1.95%
Clearmind Medicine Inc stock is traded at $0.5591, with a volume of 838.94K.
It is down -8.42% in the last 24 hours and down -52.21% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$0.6105
Open:
$0.6006
24h Volume:
838.94K
Relative Volume:
0.19
Market Cap:
$5.70M
Revenue:
-
Net Income/Loss:
$-6.64M
P/E Ratio:
-0.0309
EPS:
-18.0702
Net Cash Flow:
$-5.60M
1W Performance:
-19.67%
1M Performance:
-52.21%
6M Performance:
-98.11%
1Y Performance:
-98.54%
1-Day Range:
$0.5202
$0.6006
1-Week Range:
$0.5202
$0.7345
52-Week Range:
$0.5202
$52.40
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.5591 | 6.22M | 0 | -6.64M | -5.60M | -18.07 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind files European patent for PTSD treatment compounds By Investing.com - Investing.com South Africa
Clearmind files European patent for PTSD treatment compounds - Investing.com UK
Clearmind Medicine Inc. Files European Patent Application for Innovative Psychedelic Compounds Targeting PTSD Treatment - Quiver Quantitative
Clearmind (Nasdaq: CMND) files European patent for PTSD psychedelics - Stock Titan
Clearmind Medicine Announces Filing Of European Patent Application For Novel Psychedelic Compounds For The Treatment Of Ptsd - TradingView
Clearmind seeks European patent for psychedelic PTSD compounds - Stock Titan
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic ... - Caledonian Record
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD - marketscreener.com
CMND Stock Price, Quote & Chart | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Clearmind Medicine (NASDAQ: CMND) registers 22.6M resale shares tied to $10M notes - Stock Titan
Clearmind Medicine amends securities agreement and announces board changes - Investing.com
Leadership shifts at Clearmind Medicine (NASDAQ: CMND) as chair exits - Stock Titan
Clearmind shares surge as CMND-100 achieves primary endpoint in clinical trial - MSN
Clearmind Announces Changes To Senior Management As It Accelerates Development Of Its IP Portfolio - TMX Newsfile
Clearmind Medicine regains compliance with Nasdaq - MSN
Clearmind Medicine to enact 1-for-40 reverse share split; shares down - MSN
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation - The Manila Times
Clearmind Medicine Inc. Pursues Breakthrough Therapy Designation for Alcohol Use Disorder Treatment CMND-100 Following Positive Clinical Trial Results - Quiver Quantitative
Clearmind (NASDAQ: CMND) explores FDA breakthrough path for CMND-100 in AUD - Stock Titan
Alcohol disorder treatment from Clearmind eyes FDA breakthrough path - Stock Titan
CMND stock set for biggest intraday gains in over three years — here’s why retail is eyeing further upside - MSN
Clearmind Medicine Inc. (CMND) Stock Price Today - MEXC Exchange
CMND Technical Analysis | Trend, Signals & Chart Patterns | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Why is Clearmind Medicine stock sliding on Wednesday? - MSN
Why Is Clearmind Medicine Stock Sliding On Wednesday? - Benzinga
Crude Oil Surges Over 6%; Investar Holding Shares Gain Following Q1 Earnings - Sahm
US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results - Sahm
Clearmind Medicine (NASDAQ: CMND) adds $2.7M notes and converts $2.68M to shares - Stock Titan
Dow Gains Over 200 Points; US Retail Sales Top Estimates - Sahm
Clearmind’s CMND-100 meets primary endpoint in phase I/IIa trial - Investing.com India
Clearmind Medicine (CMND) issues $2.7M in new convertible promissory notes at 90% of principal - Stock Titan
Clearmind Medicine (CMND) Stock Surges 100% After Drug Trial Hit Safety Goals - MEXC Exchange
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care - The Manila Times
[6-K] Clearmind Medicine Inc. Current Report (Foreign Issuer) | CMND SEC FilingForm 6-K - Stock Titan
Trump order spotlights psychedelic drugs for veterans, Clearmind says - Stock Titan
Clearmind’s CMND-100 meets primary endpoint in phase I/IIa trial By Investing.com - Investing.com South Africa
CMND Stock Jumps As Psychedelic Tailwinds Lift Clearmind - StocksToTrade
Clearmind Medicine jumps 64.7% after CMND-100 hits key safety endpoint in early AUD study - Quiver Quantitative
Clearmind Medicine's CMND-100 Achieves Key Safety Milestone in Alcohol Use Disorder Trial: What U.S. - AD HOC NEWS
Clearmind Medicine Says Drug Candidate Met Primary Endpoint in Phase I/IIa Trial to Treat Alcohol Use Disorder - Moomoo
Clearmind Medicine (CMND) Stock Doubles as CMND-100 Passes Critical Safety Milestone - Blockonomi
Why Is Clearmind Stock Rising Monday?Clearmind Medicine (NASDAQ:CMND) - Benzinga
Clearmind Medicine CMND Stock Jumps On Psychedelic Policy Tailwinds - timothysykes.com
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):